Docoh
Loading...

ELAN Elanco Animal Health

Filed: 17 Dec 20, 4:40pm

 

 

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): December 17, 2020

 

Elanco Animal Health Incorporated

(Exact name of registrant as specified in its charter)

 

Indiana 001-38661 82-5497352

(State or other jurisdiction of

incorporation)

 (Commission File
Number)
 

(IRS Employer

Identification No.)

 

2500 Innovation Way

Greenfield, Indiana

(Address of Principal Executive Offices)

 

46140

(Zip Code)

 

(877) 352-6261

(Registrant’s Telephone Number, Including Area Code) 

 

Not Applicable

(Former Name or Former Address, If Changed since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange
on which registered
Common stock, no par value ELAN New York Stock Exchange
5.00% Tangible Equity Units ELAT New York Stock Exchange

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

 

Emerging growth company ¨ 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 8.01Other Events.

 

On December 17, 2020, Elanco Animal Health Incorporated (“Elanco”) announced the exercise in full of the underwriters’ option to purchase up to an additional 8,175,000 shares of Elanco’s common stock, no par value (the “Common Stock”), from Bayer World Investments B.V. (the “Selling Shareholder”), an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, at a price to the public of $30.25 per share, less underwriting discounts, in connection with the previously announced underwritten public offering of 54,500,000 shares of Common Stock, which closed on December 3, 2020. Elanco will not receive any proceeds from the sale of the additional shares of Common Stock by the Selling Shareholder.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

 Elanco Animal Health Incorporated
   
   
Date: December 17, 2020By:/s/ Michael-Bryant Hicks
  Name: Michael-Bryant Hicks
  Title: Executive Vice President, General Counsel and Corporate Secretary